Side-by-side · Research reference
BronchogenvsTesofensine
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BPhase 3AUTO-DRAFTED10/40 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
Tesofensine
SNDRI · Phase 3 obesity candidate
Oral · Once daily morning
01Mechanism of Action
Parameter
Bronchogen
Tesofensine
Primary target
Bronchial epithelial cellsKuzubova 2015
Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
Tesofensine
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Phase 2b + ongoing Phase 3Astrup 2008
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Frequency
—
Once daily, morning
Lower / starter dose
—
0.125 mg / day
Duration
—
24 weeks per studied cycle
Form
—
Oral capsule
Timing
—
Morning to avoid sleep disruption
Half-life
—
~9 days (very long)
04Side Effects & Safety
Parameter
Bronchogen
Tesofensine
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Insomnia
—
Dose-related; mitigate with morning timing
Dry mouth
—
Common
Nausea
—
Common
Mood changes
—
Anxiety / agitation possible
Cardiovascular events
—
Phase 3 trial monitoring; not yet FDA-cleared
Pregnancy / OB
—
Contraindicated
Absolute Contraindications
Bronchogen
—Tesofensine
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease
- ·Concurrent MAOI use
Relative Contraindications
Bronchogen
—Tesofensine
- ·Hypertension
- ·Anxiety disorder
- ·Insomnia
05Administration Protocol
Parameter
Bronchogen
Tesofensine
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
Oral capsule (investigational; not commercial).
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
Swallow whole with water, morning only.
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
Morning to mitigate insomnia. Do not dose evening.
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
Room temp ≤25 °C, dry place.
5. Caveat
—
Monitor BP + HR + mood. Avoid stimulants + MAOIs.